<i>Background and Objectives:</i> SGLT2 inhibitors are foundational in heart failure therapy, yet their impact on left ventricular (LV) remodeling immediately following acute coronary syndrome (ACS) remains less defined. Here, SLC5A2 is linked to acute coronary syndrome.